v3.26.1
Stockholders' Equity - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 6 Months Ended
May 18, 2026
Jun. 12, 2025
Dec. 18, 2024
May 31, 2026
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Jun. 04, 2025
Subsidiary, Sale of Stock [Line Items]                
Authorized shares of common stock         250,000,000   250,000,000  
Common stock, par value (in USD per share)         $ 0.001   $ 0.001  
Preferred stock, shares issued (in shares)         0   0  
Net proceeds         $ 20,338 $ 2,890    
Common stock, shares issued (in shares)         1,017,063   278,627  
Orphai Therapeutics [Member]                
Subsidiary, Sale of Stock [Line Items]                
Net proceeds from the offering $ 103,600              
As converted to common basis 3,749,231              
Pre-Funded warrants exercise price $ 19.17       $ 19.17      
Common stock, par value (in USD per share) $ 19.17              
Deferred Offering Costs $ 11,400              
Common stock, shares issued (in shares) 1,308,804              
Aggregate gross proceeds of cash exercise in full of the Common Warrants $ 72,000              
Orphai Therapeutics [Member] | Upfront                
Subsidiary, Sale of Stock [Line Items]                
Aggregate gross proceeds of private placement $ 115,000              
Series C Preferred Stock                
Subsidiary, Sale of Stock [Line Items]                
Aggregate gross proceeds of cash exercise in full of the Common Warrants       $ 11,000        
Series C Preferred Stock | Orphai Therapeutics [Member]                
Subsidiary, Sale of Stock [Line Items]                
As converted to common basis 7,498,447              
Shares issued, price per share $ 797.5              
Pre-Funded warrants exercise price $ 996.9       $ 996.9      
Stock issued during period shares acquisitions 144,200.633              
Preferred stock, shares issued (in shares) 72,100.322       10,964.505      
Common Warrant | Orphai Therapeutics [Member]                
Subsidiary, Sale of Stock [Line Items]                
As converted to common basis 4,319,400              
Pre-Funded warrants exercise price         $ 19.17      
Common stock, shares issued (in shares)         570,169      
Aggregate gross proceeds of cash exercise in full of the Common Warrants $ 11,000              
Common Warrant | Series C Preferred Stock | Orphai Therapeutics [Member]                
Subsidiary, Sale of Stock [Line Items]                
Preferred stock, shares issued (in shares) 83,064.827              
Controlled Equity Offering Sales Agreement                
Subsidiary, Sale of Stock [Line Items]                
Maximum aggregate offering price     $ 75,000          
Private Placement                
Subsidiary, Sale of Stock [Line Items]                
Net proceeds         $ 20,300      
Issuance of stock (in shares)         526,435      
Common stock, shares issued (in shares)   33,360            
Aggregate gross proceeds of private placement   $ 11,500            
Private Placement | Orphai Therapeutics [Member]                
Subsidiary, Sale of Stock [Line Items]                
Aggregate gross proceeds of private placement $ 187,000              
Aggregate gross proceeds of cash exercise in full of the Common Warrants 72,000              
Private Placement | Pre-Funded Warants [Member]                
Subsidiary, Sale of Stock [Line Items]                
Pre-Funded warrants exercise price   $ 0.2            
Common stock, shares issued (in shares)   10,000            
Private Placement | Common Warrant                
Subsidiary, Sale of Stock [Line Items]                
Pre-Funded warrants exercise price   $ 240            
Common stock, shares issued (in shares)   43,360            
Aggregate gross proceeds of cash exercise in full of the Common Warrants   $ 10,400            
Private Placement | Common Warrant | Orphai Therapeutics [Member]                
Subsidiary, Sale of Stock [Line Items]                
Aggregate gross proceeds of cash exercise in full of the Common Warrants $ 72,000              
ATM Program                
Subsidiary, Sale of Stock [Line Items]                
Common stock reserved for issuance (in shares)         47,500,000      
Maximum                
Subsidiary, Sale of Stock [Line Items]                
Authorized shares of common stock               250,000,000
Minimum                
Subsidiary, Sale of Stock [Line Items]                
Authorized shares of common stock               100,000,000